EP102
EP102 is an orally active, selective inhibitor of the METTL3/METTL14 complex with an IC50 of 2 nM. EP102 reduces intracellular N6-methyladenosine levels, inhibits cancer cell proliferation, and thereby suppresses tumor growth in mouse models. EP102 is applicable for the research of acute myeloid leukemia, ovarian solid tumors and advanced solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3050818-07-7
- 分子式: C27H32N6OS
- 分子量:488.65
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
|
CYP3A4 0.9 nM (IC50) |
CYP3A5 16 nM (IC50) |
EP102 (72 h) inhibits the viability of Kasumi-1, MV-4-11, Calu-6, A549, FaDu, SK-OV-3, and Caov-3 human cancer cell lines with IC50 values ranging from 31 nM to 225 nM[1].
EP102 inhibits intracellular m6A levels in Kasumi-1, MV-4-11, Calu-6, A549, FaDu, and SK-OV-3 human cancer cell lines with IC50 values ranging from 6 nM to 19 nM[1].
EP102 exhibits metabolic stability in rat, minipig, and human liver microsomes with half-lives of 149 min, 44 min, and 53 min, respectively[1].
EP102 selectively inhibits human CYP3A4 with an IC50 of 0.9 μM and CYP3A5 with an IC50 of 16 μM, while not significantly inhibiting the other 8 tested major human CYPs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kasumi-1, MV-4-11, Calu-6, A549, FaDu, and SK-OV-3 human cancer cell lines
-
Concentration:IC50
-
Incubation Time:/
-
Result:Downregulated the intracellular m6A levels in with IC50 values ranging from 6 nM to 19 nM.
EP102 (47 mg/kg; p.o.; TIW; 32 days) achieves >90% tumor growth inhibition and reduces metastasis in an intraovarian mouse xenograft model of ovarian cancer when dosed orally at 47 mg/kg three times weekly[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice with Acute myeloid leukemia (AML) (female; disseminated xenograft model via intravenous injection of 2 × 10^6 MV-4-11-Luc-mCh-Puro cells)[1]
-
Dosage:20 mg/kg; 47 mg/kg
-
Administration:p.o.; QD (20 mg/kg), TIW (47 mg/kg); 4 weeks
-
Result:Restricted AML tumor spread as shown by bioluminescence imaging with both dosing regimens.
Reduced levels of hCD45+ human AML cells in bone marrow with both dosing regimens.
Showed no depletion of mouse mCD45+ cells.
Demonstrated superior efficacy with the 47 mg/kg TIW regimen compared to the 20 mg/kg QD regimen.
Maintained stable body weights in treated mice, indicating well-tolerated treatment.
-
Animal Model:Balb/c mice with Ovarian cancer (female; intraovarian xenograft model via implant of SK-OV-3-Luc cells)[1]
-
Dosage:47 mg/kg
-
Administration:p.o.; TIW; 32 days
-
Result:Achieved >90% tumor growth inhibition (TGI) relative to vehicle controls over the 32-day treatment period via bioluminescence measurement.
Reduced metastasis in the intestines, an effect not observed with the positive control Olaparib.
Maintained stable body weights in treated mice and showed no macroscopic adverse events, indicating well-tolerated treatment.
化学情報
-
CAS 番号 3050818-07-7
-
分子量 488.65
-
分子式 C27H32N6OS
-
SMILES
C1(C2(COC2)C3=NN=C(C4=CC(C5CC5)=CN=C4)S3)=NC=C(N6CCC[C@@H](NCC7CC7)C6)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)